Moleculin completes dosing in Part A of Annamycin pivotal trial
Moleculin completes dosing in Phase 2/3 MIRACLE trial evaluating Annamycin. The company is on track to report comprehensive Part A data in Q1 2027, which is expected to support dose selection for Part B.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed